Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
RayzeBio, Inc.
Study ID
NCT07165132
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RYZ401 — DRUG
    Ac-225

Study Details

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Key Dates

Start date
Dec 3, 2025
Status verified
Jun 2026
Primary completion
Feb 28, 2027
Completion
Apr 30, 2033

Study Design

Enrollment
104 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation, Dose Expansion

Primary Outcome Measure

Dose Escalation [ Time Frame: Incidence of DLTs during the first 4 weeks of RYZ401 treatment ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Research FacilityIowa CityIowa52242-
Research FacilityLexingtonKentucky40536-
Research FacilitySt LouisMissouri63104-
Research FacilitySt LouisMissouri63110-
Research FacilityColumbusOhio43210-
Research FacilityNashvilleTennessee37232-
Research FacilitySalt Lake CityUtah84112-

Find similar trials in Iowa City, IA

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Research Facility· Iowa City, IAResearch Facility· Lexington, KYResearch Facility· St Louis, MOResearch Facility· Columbus, OHResearch Facility· Nashville, TNResearch Facility· Salt Lake City, UT

Related Studies